
Pharmacally
Lenacapavir
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Lenacapavir
Clinical TrialsGilead Reports Higher PrEP Persistence with Lenacapavir in PURPOSE 5Gilead Sciences reported significantly higher one-year HIV prevention persistence with twice-yearly injectable lenacapavir than daily oral F/TDF in its Phase 2 PURPOSE 5 trial.Fact-Checked
GenericsDr. Reddy’s Wins FDA Approval for Generic Lenacapavir Across LMICsDr. Reddy’s Laboratories has secured tentative FDA approval for its generic twice-yearly injectable lenacapavir for HIV prevention.Fact-Checked
Health TidingsGilead Expands Lenacapavir Licenses to Support Potential Once-Yearly HIV PrEP in 120 CountriesGilead Sciences has expanded six royalty-free lenacapavir licensing agreements to cover investigational once-yearly HIV PrEP across 120 high-incidence, resource-limited countries as the Phase 3 PURPOSE 365 trial continues.Fact-Checked
Health TidingsCDSCO Expert Committee Recommends Bioequivalence and Phase III Trial Waivers for Generic Lenacapavir PrEPIndia’s CDSCO Subject Expert Committee has recommended bioequivalence and Phase III clinical trial waivers for generic lenacapavir injection for HIV PrEP from Dr Reddy’s Laboratories and Emcure Pharmaceuticals…Fact-Checked
Clinical TrialsGilead to Present Long-Term Lenacapavir, ISLEND and HIV Pipeline Data at AIDS 2026Gilead Sciences will showcase new HIV prevention and treatment data at AIDS 2026, including long-term Phase 3 PURPOSE trial results supporting twice-yearly lenacapavir for PrEP, full Phase 3…Fact-Checked
Health TidingsSouth Africa Rolls Out Lenacapavir to Prevent HIVGilead Sciences and global health partners have introduced lenacapavir (Yeztugo®) for HIV prevention in South Africa, marking the first large‑scale rollout of a twice‑yearly injectable PrEP.Fact-Checked
Health TidingsPartnership Capital Fuels Lenacapavir’s Surge into the HIV Prevention FrontlinesGilead Sciences, alongside PEPFAR and The Global Fund, will expand access to lenacapavir, aiming to reach up to 3 million people in high-incidence regions by 2028 while advancing…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.